Compare · PALI vs TIL
PALI vs TIL
Side-by-side comparison of Palisade Bio Inc. (PALI) and Instil Bio Inc. (TIL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PALI and TIL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- PALI is the larger of the two at $302.0M, about 5.5x TIL ($54.7M).
- Over the past year, PALI is up 151.4% and TIL is down 76.7% - PALI leads by 228.2 points.
- PALI has hit the wire 2 times in the past 4 weeks while TIL has been quiet.
- TIL has more recent analyst coverage (10 ratings vs 7 for PALI).
- Company
- Palisade Bio Inc.
- Instil Bio Inc.
- Price
- $1.74+0.00%
- $8.21+1.17%
- Market cap
- $302.0M
- $54.7M
- 1M return
- -12.59%
- +4.58%
- 1Y return
- +151.45%
- -76.74%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 2
- 0
- Recent ratings
- 7
- 10
Palisade Bio Inc.
Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress, such as results from reduced blood flow to the intestine, infections, and surgery. The company was founded in 2005 and is based in Carlsbad, California.
Instil Bio Inc.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.
Latest PALI
- Palisade Bio to Participate in the Jefferies Global Healthcare Conference
- SEC Form EFFECT filed by Palisade Bio Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Palisade Bio Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Palisade Bio Inc.
- SEC Form SCHEDULE 13G filed by Palisade Bio Inc.
- SEC Form S-3 filed by Palisade Bio Inc.
- Palisade Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
- SEC Form 10-Q filed by Palisade Bio Inc.
- Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis
Latest TIL
- SEC Form 10-Q filed by Instil Bio Inc.
- Instil Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form DEFA14A filed by Instil Bio Inc.
- SEC Form DEF 14A filed by Instil Bio Inc.
- Instil Bio Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- SEC Form S-8 filed by Instil Bio Inc.
- SEC Form 10-K filed by Instil Bio Inc.
- Instil Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update